Dipeptidyl peptidases and related proteins: Multifaceted markers and therapeutic targets

Clinical Chemistry and Laboratory Medicine

Volumn 47, Issue 3, 2009, Pages 245-247

  De Meester, Ingrid ^a   Scharpé, Simon ^a   Lambeir, Anne Marie ^a  

^a UNIVERSITY OF ANTWERP   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

BRAIN NATRIURETIC PEPTIDE; COLLAGEN; DIPEPTIDYL PEPTIDASE; DIPEPTIDYL PEPTIDASE 10; DIPEPTIDYL PEPTIDASE 6; DIPEPTIDYL PEPTIDASE IV; DIPEPTIDYL PEPTIDASE IV INHIBITOR; EFFICIB; GLUCAGON LIKE PEPTIDE 1; HEMOGLOBIN A1C; INCRETIN; METFORMIN; METFORMIN PLUS SITAGLIPTIN; METFORMIN PLUS VILDAGLIPTIN; ORAL ANTIDIABETIC AGENT; PLACEBO; PROLINE; PROLINE DIPEPTIDASE; SITAGLIPTIN; STROMAL CELL DERIVED FACTOR 1; STROMAL CELL DERIVED FACTOR 1ALPHA; SULFONYLUREA; UNCLASSIFIED DRUG; VILDAGLIPTIN;

ANAPHYLAXIS; ANGIONEUROTIC EDEMA; ASTHMA; DRUG EFFICACY; DRUG ERUPTION; DRUG HYPERSENSITIVITY; DRUG INHIBITION; DRUG MECHANISM; DRUG SAFETY; DRUG TARGETING; DRUG WITHDRAWAL; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME REPLACEMENT; EXFOLIATIVE DERMATITIS; GLUCAGON RELEASE; GLYCEMIC CONTROL; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; INFECTION; INSULIN RELEASE; LIVER DYSFUNCTION; MUCOPOLYSACCHARIDOSIS; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN TARGETING; REVIEW; THYROID CARCINOMA; UNSPECIFIED SIDE EFFECT;

ANTIGENS, CD26; BIOLOGICAL MARKERS; DIABETES MELLITUS, TYPE 2; DIPEPTIDYL PEPTIDASES; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; HUMANS; NERVE TISSUE PROTEINS; PEPTIDE HYDROLASES; POTASSIUM CHANNELS;

EID: 63849222988     PISSN: 14346621     EISSN: 14374331     Source Type: Journal    
DOI: 10.1515/CCLM.2009.085     Document Type: Review

References (19)

1. Lambeir AM, Durinx C, Scharpe S, De Meester I. Dipeptidyl-peptidase IV from bench to bedside: an update on structural properties, functions, and clinical aspects of the enzyme DPP IV. Crit Rev Clin Lab Sci 2003;40:209-94.
2. de Micco C, Savchenko V, Giorgi R, Sebag F, Henry JF. Utility of malignancy markers in fine-needle aspiration cytology of thyroid nodules: comparison of Hector Battifora mesothelial antigen-1, thyroid peroxidase and dipeptidyl aminopeptidase IV. Br J Cancer 2008;98:818- 23.
3. Ibegbu CC, Xu YX, Fillos D, Radziewicz H, Grakoui A, Kourtis AP. Differential expression of CD26 on virus-specific CD8(q) T cells during active, latent and resolved infection. Immunology 2008 (E-pub ahead of print) doi 10.1111/j.1365-2567.2008.02899.
4. pos memory T-cells in the autograftpredict early progression or recurrence in patients undergoing high-dose chemotherapy and autologous haematopoietic progenitor-cell transplantation. Clin Chem Lab Med 2008;46:A17.
5. Van der Veken P, Haemers A, Augustyns K. Prolyl peptidases related to dipeptidyl peptidase IV: potential of specific inhibitors in drug discovery. Curr Top Med Chem 2007;7:621-35.
6. Lendeckel U, Bank U, Reinhold D, editors. Dipeptidyl aminopeptidases: basic science and clinical applications. New York: Springer, 2006:239 pp. 7. Hildebrandt M, Klapp B, Hoffmann T, Demuth H-U, editors. Dipeptidyl aminopeptidases in health and disease. New York: Kluwer Academic/Plenum Publishers, 2003: 359 pp.
7. All authors. Abstracts 3rd International Conference on Dipeptidyl Peptidase and Related Proteins. Clin Chem Lab Med 2008;46:A1-A43.
8. Connolly BA, Sanford DG, Chiluwal AK, Healey SE, Peters DE, Dimare MT, et al. Dipeptide boronic acid inhibitors of dipeptidyl peptidase IV: determinants of potency and in vivo efficacy and safety. J Med Chem 2008;51:6005-13.
9. Allen M, Heinzmann A, Noguchi E, Abecasis G, Broxholme J, Ponting CP, et al. Positional cloning of a novel gene influencing asthma from chromosome 2q14. Nat Genet 2003;35:258-63.
10. Deacon CF, Carr RD, Holst JJ. DPP4 inhibitor therapy: new directions in the treatment of type 2 diabetes. Front Biosci 2008;13:1780-94.
11. Drucker DJ. The role of gut hormones in glucose homeostasis. J Clin Invest 2007;117:24-32.
12. Amori RE, Lau J, Pittas AG. Efficacy and safety of incretin therapy in type 2 diabetes: systematic review and metaanalysis. J Am Med Assoc 2007;298:194-206.
13. Richter B, Bandeira-Echtler E, Bergerhoff K, Lerch C. Emerging role of dipeptidyl peptidase-4 inhibitors in the management of type 2 diabetes. Vasc Health Risk Manag 2008;4:753-68.
14. Lambeir AM, Scharpe S, De Meester I. DPP4 inhibitors for diabetes - what next? Biochem Pharmacol 2008;76: 1637-43.
15. Focosi D, Kast RE, Metelli MR, Benedetti E, Galimberti S, Papineschi F, et al. Enhancement of hematopoietic stem cell engraftment by inhibition of CXCL12 proteolysis with sitagliptin, an oral dipeptidyl-peptidase IV inhibitor: a report in a case of delayed graft failure. Leuk Res 2009;33:178-204.
16. Jost MM, Lamerz J, Tammen H, Menzel C, De Meester I, Lambeir AM, et al. In vivo profiling of DPP4 inhibitors reveals alterations in collagen metabolism and accumulation of an amyloid peptide in rat plasma. Biochem Pharmacol 2009;77:228-37.
17. Tagore DM, Nolte WM, Neveu JM, Rangel R, Guzman- Rojas L, Pasqualini R, et al. Peptidase substrates via global peptide profiling. Nat Chem Biol 2009;5:23-5.
18. Phang JM, Pandhare J, Liu Y. The metabolism of proline as microenvironmental stress substrate. J Nutr 2008; 138:2008S-15S.
19. Beesley CE, Young EP, Finnegan N, Jackson M, Mills K, Vellodi A, et al. Discovery of a new biomarker for the mucopolysaccaridoses (MPS), dipeptidyl peptidase IV (DPP-IV; CD26), by SELDI-TOF mass spectrometry. Mol Gen Metab 2009; doi:10.1016/j.ymgme.2008.12.002.